Financial Performance - Revenues for Q2 2024 increased by 30.0% year-over-year to 78.1million,comparedto60.1 million in Q2 2023[1] - Net Loss for Q2 2024 was (18.1)million,anincreaseof12.6 million from (5.5)millioninQ22023[2]−AdjustedEBITDAforQ22024decreasedby2.7 million to 1.6million,downfrom4.4 million in Q2 2023[4] - Free Cash Flow for Q2 2024 decreased by 12.3millionto(11.2) million, compared to 1.1millioninQ22023[4]−TotalcomprehensivelossforQ22024was(18,170,000), compared to (5,326,000)inQ22023[24]−NetincomeforthesixmonthsendedJune30,2024,wasalossof26,183 thousand, compared to a loss of 12,723thousandforthesameperiodin2023[25]−TheadjustedEBITDAforthesixmonthsendedJune30,2024,was5,906 thousand, down from 8,698thousandforthesameperiodin2023[27]−CashflowsfromoperatingactivitiesforthesixmonthsendedJune30,2024,resultedinanetcashusedof6,742 thousand, an improvement from 11,204thousandusedinthesameperiodin2023[25]−FreecashflowforthesixmonthsendedJune30,2024,was(10,796) thousand, compared to (13,752)thousandforthesameperiodin2023[29]LiquidityandAssets−TotalavailableliquidityasofJune30,2024,was55.8 million, a 54.1% increase from June 30, 2023[2] - Total current assets decreased to 105,313,000asofJune30,2024,downfrom109,313,000 at the end of 2023[20] - Cash and cash equivalents increased slightly to 30,832,000asofJune30,2024,from30,278,000 at the end of 2023[20] - The cash and cash equivalents at the end of the period on June 30, 2024, were 30,832thousand,comparedto11,231 thousand at the end of the same period in 2023[25] Backlog and Contracts - Contracted Backlog increased by 29.9% year-over-year to 354millionasofJune30,2024,comparedto273 million on June 30, 2023[1] - Book-to-Bill ratio was 1.28 on a last twelve month (LTM) basis as of Q2 2024, compared to 1.49 in Q2 2023[4] - The book-to-bill ratio for the three months ended June 30, 2024, was 1.47, significantly higher than 0.76 for the same period in 2023[31] - Total contracts awarded for the three months ended June 30, 2024, amounted to 114,437thousand,comparedto45,646 thousand for the same period in 2023[31] - Organic backlog increased to 372,790thousandasofJune30,2024,comparedto313,057 thousand as of December 31, 2023, reflecting a growth of 19.1%[33] - Contracted backlog at the end of the period was 354,344thousand,downfrom372,790 thousand as of December 31, 2023, representing a decline of 4.5%[33] - The company expects all amounts reflected in contracted backlog to ultimately be fully funded despite potential terminations or amendments[37] Expenses and Liabilities - Operating loss for Q2 2024 was (7,130,000),worseningfrom(3,856,000) in Q2 2023[24] - Total liabilities increased to 229,844,000asofJune30,2024,comparedto218,444,000 at the end of 2023[20] - Convertible preferred stock had a liquidation preference of 242,381,000asofJune30,2024,upfrom187,780,000 at the end of 2023[22] - Research and development expenses for Q2 2024 were 1,748,000,downfrom2,070,000 in Q2 2023[24] - The company incurred acquisition costs related to due diligence and integration expenses, impacting financial performance[26] Growth and Innovation - The company submitted approximately 1.9billioninbidsyear−to−datein2024,indicatingstronggrowthmomentum[5]−ThecompanywasawardedaprimecontractfortheSabreSatVLEOplatformunderDARPA′sOtterprogram,highlightingitsinnovationandmarketexpansionefforts[1]−Organicadditionsduringtheperiodwere149,538 thousand, down from 300,042thousandinthepreviousperiod,indicatingadecreaseof50(165,903) thousand, an improvement from (243,800)thousandinthepriorperiod[33]−Foreigncurrencytranslationimpactsonbacklogwere(2,081) thousand for the current period, compared to $3,491 thousand in the previous period[33]